;PMID: 10820437
;source_file_1910.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..156] = [t:46..156]
;2)section:[e:160..215] = [t:160..215]
;3)section:[e:219..295] = [t:219..295]
;4)sentence:[e:299..377] = [t:299..377]
;5)sentence:[e:379..596] = [t:379..596]
;6)sentence:[e:597..765] = [t:597..765]
;7)sentence:[e:767..1069] = [t:767..1069]
;8)sentence:[e:1070..1221] = [t:1070..1221]
;9)sentence:[e:1222..1453] = [t:1222..1453]
;10)sentence:[e:1454..1653] = [t:1454..1653]
;11)sentence:[e:1654..1756] = [t:1654..1756]
;12)sentence:[e:1757..1901] = [t:1757..1901]
;13)sentence:[e:1902..2137] = [t:1902..2137]
;14)sentence:[e:2138..2395] = [t:2138..2395]
;15)sentence:[e:2396..2644] = [t:2396..2644]
;16)section:[e:2645..2676] = [t:2645..2676]
;17)section:[e:2680..2725] = [t:2680..2725]

;section 0 Span:0..40
;J Neurosci Res. 2000 Jun 1;60(5):656-65.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..10] Neurosci) (NNP:[11..14] Res) (.:[14..15] .)
        (CD:[16..20] 2000) (JJ:[21..24] Jun) (CD:[25..29] 1;60)
        (-LRB-:[29..30] -LRB-) (CD:[30..31] 5) (-RRB-:[31..32] -RRB-)
        (CD:[32..39] :656-65) (.:[39..40] .)))

;sentence 1 Span:46..156
;Human neuroblastoma SH-SY5Y cell line: neurosteroid-producing cell line
;relying  on cytoskeletal organization.
;[85..97]:substance:"neurosteroid"
(SENT
  (NP-HLN
    (NP (JJ:[46..51] Human) (NN:[52..65] neuroblastoma) (NN:[66..73] SH-SY5Y)
        (NN:[74..78] cell) (NN:[79..83] line))
    (::[83..84] :)
    (NP
      (NP
        (ADJP (NN:[85..97] neurosteroid) (HYPH:[97..98] -)
              (VBG:[98..107] producing))
        (NN:[108..112] cell) (NN:[113..117] line))
      (VP (VBG:[118..125] relying)
        (PP-CLR (IN:[127..129] on)
          (NP (JJ:[130..142] cytoskeletal) (NN:[143..155] organization)))))
    (.:[155..156] .)))

;section 2 Span:160..215
;Guarneri P, Cascio C, Piccoli T, Piccoli F, Guarneri R.
(SEC
  (FRAG (NNP:[160..168] Guarneri) (NNP:[169..171] P,) (NNP:[172..178] Cascio)
        (NNP:[179..180] C) (,:[180..181] ,) (NNP:[182..189] Piccoli)
        (NNP:[190..191] T) (,:[191..192] ,) (NNP:[193..200] Piccoli)
        (NNP:[201..202] F) (,:[202..203] ,) (NNP:[204..212] Guarneri)
        (NNP:[213..215] R.)))

;section 3 Span:219..295
;Istituto di Biologia dello Sviluppo, Palermo, Italy. pguarneri@ibs.pa.cnr.it
(SEC
  (FRAG (NNP:[219..227] Istituto) (NNP:[228..230] di) (NNP:[231..239] Biologia)
        (NNP:[240..245] dello) (NNP:[246..254] Sviluppo) (,:[254..255] ,)
        (NNP:[256..263] Palermo) (,:[263..264] ,) (NNP:[265..270] Italy)
        (.:[270..271] .) ('':[272..285] pguarneri@ibs) (VBD:[285..288] .pa)
        (``:[288..292] .cnr) (NN:[292..295] .it)))

;sentence 4 Span:299..377
;Pregnenolone, the precursor of all steroids, is synthesized by CNS
;structures.
;[299..311]:substance:"Pregnenolone"
;[317..326]:substance:"precursor"
;[334..342]:substance:"steroids"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[299..311] Pregnenolone))
      (,:[311..312] ,)
      (NP
        (NP (DT:[313..316] the) (NN:[317..326] precursor))
        (PP (IN:[327..329] of)
          (NP (DT:[330..333] all) (NNS:[334..342] steroids)))))
    (,:[342..343] ,)
    (VP (VBZ:[344..346] is)
      (VP (VBN:[347..358] synthesized)
        (NP-1 (-NONE-:[358..358] *))
        (PP (IN:[359..361] by)
          (NP-LGS (NN:[362..365] CNS) (NNS:[366..376] structures)))))
    (.:[376..377] .)))

;sentence 5 Span:379..596
;The synthesis requires an obligatory step involving cholesterol transport to 
;mitochondrial cytochrome P450-cholesterol side chain cleavage (cytP450scc), 
;although the underlying mechanism(s) are still mostly unknown.
;[431..442]:substance:"cholesterol"
;[471..518]:cyp450:"cytochrome P450-cholesterol side chain cleavage"
;[520..530]:cyp450:"cytP450scc"
(SENT
  (S
    (NP-SBJ (DT:[379..382] The) (NN:[383..392] synthesis))
    (VP (VBZ:[393..401] requires)
      (NP
        (NP (DT:[402..404] an) (JJ:[405..415] obligatory) (NN:[416..420] step))
        (VP (VBG:[421..430] involving)
          (NP
            (NP (NN:[431..442] cholesterol) (NN:[443..452] transport))
            (PP (TO:[453..455] to)
              (NP
                (NP (JJ:[457..470] mitochondrial)
                  
                  (NML
                    (NML (NN:[471..481] cytochrome) (NN:[482..486] P450))
                    (HYPH:[486..487] -)
                    (NML (NN:[487..498] cholesterol) (NN:[499..503] side)
                         (NN:[504..509] chain)))
                  (NN:[510..518] cleavage))
                (NP (-LRB-:[519..520] -LRB-) (NN:[520..530] cytP450scc)
                    (-RRB-:[530..531] -RRB-)))))))
      (,:[531..532] ,)
      (SBAR-ADV (IN:[534..542] although)
        (S
          (NP-SBJ (DT:[543..546] the) (VBG:[547..557] underlying)
                  (NNS:[558..570] mechanism-LRB-s-RRB-))
          (VP (VBP:[571..574] are)
            (ADVP (RB:[575..580] still))
            (ADJP-PRD (RB:[581..587] mostly) (JJ:[588..595] unknown))))))
    (.:[595..596] .)))

;sentence 6 Span:597..765
;We used the human  neuroblastoma SH-SY5Y cell line to investigate cytP450scc
;expression and  activity and to establish a role of cytoskeleton in
;pregnenolone synthesis.
;[663..673]:cyp450:"cytP450scc"
;[742..754]:substance:"pregnenolone"
(SENT
  (S
    (NP-SBJ (PRP:[597..599] We))
    (VP (VBD:[600..604] used)
      (NP (DT:[605..608] the) (JJ:[609..614] human)
          (NN:[616..629] neuroblastoma) (NN:[630..637] SH-SY5Y)
          (NN:[638..642] cell) (NN:[643..647] line))
      (S-PRP
        (NP-SBJ (-NONE-:[647..647] *))
        (VP
          (VP (TO:[648..650] to)
            (VP (VB:[651..662] investigate)
              (NP
                (NP
                  (NML-1 (NN:[663..673] cytP450scc))
                  (NN:[674..684] expression))
                (CC:[685..688] and)
                (NP
                  (NML-1 (-NONE-:[688..688] *P*))
                  (NN:[690..698] activity)))))
          (CC:[699..702] and)
          (VP (TO:[703..705] to)
            (VP (VB:[706..715] establish)
              (NP
                (NP (DT:[716..717] a) (NN:[718..722] role))
                (PP (IN:[723..725] of)
                  (NP (NN:[726..738] cytoskeleton))))
              (PP-LOC (IN:[739..741] in)
                (NP (NN:[742..754] pregnenolone) (NN:[755..764] synthesis))))))))
    (.:[764..765] .)))

;sentence 7 Span:767..1069
;Immunocytochemical and biochemical approaches revealed that undifferentiated
;as  well as differentiated cells either by retinoic acid (RA) or phorbol
;ester  12-O-tetradecanoylphorbol-13-acetate (TPA), possess cytP450scc and
;rapidly  synthesize pregnenolone in the presence of a NADPH-generating
;system.
;[887..900]:substance:"retinoic acid"
;[902..904]:substance:"RA"
;[909..922]:substance:"phorbol ester"
;[924..960]:substance:"12-O-tetradecanoylphorbol-13-acetate"
;[962..965]:substance:"TPA"
;[976..986]:cyp450:"cytP450scc"
;[1011..1023]:substance:"pregnenolone"
;[1045..1050]:substance:"NADPH"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[767..785] Immunocytochemical)
        (NML-2 (-NONE-:[785..785] *P*)))
      (CC:[786..789] and)
      (NP (JJ:[790..801] biochemical)
        (NML-2 (NNS:[802..812] approaches))))
    (VP (VBD:[813..821] revealed)
      (SBAR (IN:[822..826] that)
        (S
          (NP-SBJ
            (NP (JJ:[827..843] undifferentiated)
              (NML-1 (-NONE-:[843..843] *P*)))
            (CONJP (RB:[844..846] as) (RB:[848..852] well) (IN:[853..855] as))
            (NP
              (NP (VBN:[856..870] differentiated)
                (NML-1 (NNS:[871..876] cells)))
              (PP (CC:[877..883] either) (IN:[884..886] by)
                (NP
                  (NP
                    (NP (JJ:[887..895] retinoic) (NN:[896..900] acid))
                    (NP (-LRB-:[901..902] -LRB-) (NN:[902..904] RA)
                        (-RRB-:[904..905] -RRB-)))
                  (CC:[906..908] or)
                  (NP
                    (NP
                       (NN:[909..916] phorbol) (NN:[917..922] ester)
                      (NN:[924..960] 12-O-tetradecanoylphorbol-13-acetate))
                    (NP (-LRB-:[961..962] -LRB-) (NN:[962..965] TPA)
                        (-RRB-:[965..966] -RRB-)))))))
          (,:[966..967] ,)
          (VP
            (VP (VBP:[968..975] possess)
              (NP (NN:[976..986] cytP450scc)))
            (CC:[987..990] and)
            (VP
              (ADVP (RB:[991..998] rapidly))
              (VBP:[1000..1010] synthesize)
              (NP (NN:[1011..1023] pregnenolone))
              (PP (IN:[1024..1026] in)
                (NP
                  (NP (DT:[1027..1030] the) (NN:[1031..1039] presence))
                  (PP (IN:[1040..1042] of)
                    (NP (DT:[1043..1044] a)
                      (ADJP (NN:[1045..1050] NADPH) (HYPH:[1050..1051] -)
                            (VBG:[1051..1061] generating))
                      (NN:[1062..1068] system))))))))))
    (.:[1068..1069] .)))

;sentence 8 Span:1070..1221
;The newly  neurosteroid formation by SH-SY5Y cells was increased by
;22R-hydroxycholesterol  and blocked by the cytP450scc inhibitor,
;aminoglutethimide.
;[1081..1093]:substance:"neurosteroid"
;[1138..1160]:substance:"22R-hydroxycholesterol"
;[1181..1191]:cyp450:"cytP450scc"
;[1192..1201]:substance:"inhibitor"
;[1203..1220]:substance:"aminoglutethimide"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1070..1073] The)
        (ADJP (RB:[1074..1079] newly) (JJ:[1081..1093] neurosteroid))
        (NN:[1094..1103] formation))
      (PP (IN:[1104..1106] by)
        (NP (NN:[1107..1114] SH-SY5Y) (NNS:[1115..1120] cells))))
    (VP (VBD:[1121..1124] was)
      (VP
        (VP (VBN:[1125..1134] increased)
          (NP-1 (-NONE-:[1134..1134] *))
          (PP (IN:[1135..1137] by)
            (NP-LGS (NN:[1138..1160] 22R-hydroxycholesterol))))
        (CC:[1162..1165] and)
        (VP (VBN:[1166..1173] blocked)
          (PP (IN:[1174..1176] by)
            (NP-LGS
              (NP (DT:[1177..1180] the) (NN:[1181..1191] cytP450scc)
                  (NN:[1192..1201] inhibitor))
              (,:[1201..1202] ,)
              (NP (NN:[1203..1220] aminoglutethimide)))))))
    (.:[1220..1221] .)))

;sentence 9 Span:1222..1453
;When trilostane was  used to inhibit 3beta-hydroxysteroid dehydrogenase
;catalyzing pregnenolone  conversion into progesterone, a higher pregnenolone
;accumulation occurred in  TPA-differentiated cells than in RA-differentiated
;ones.
;[1227..1237]:substance:"trilostane"
;[1259..1293]:substance:"3beta-hydroxysteroid dehydrogenase"
;[1305..1317]:substance:"pregnenolone"
;[1335..1347]:substance:"progesterone"
;[1358..1370]:substance:"pregnenolone"
;[1397..1400]:substance:"TPA"
;[1430..1432]:substance:"RA"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-2 (WRB:[1222..1226] When))
      (S
        (NP-SBJ (NN:[1227..1237] trilostane))
        (VP (VBD:[1238..1241] was)
          (VP (VBN:[1243..1247] used)
            (S-PRP
              (NP-SBJ (-NONE-:[1247..1247] *))
              (VP (TO:[1248..1250] to)
                (VP (VB:[1251..1258] inhibit)
                  (S
                    (NP-SBJ (NN:[1259..1279] 3beta-hydroxysteroid)
                            (NN:[1280..1293] dehydrogenase))
                    (VP (VBG:[1294..1304] catalyzing)
                      (NP (NN:[1305..1317] pregnenolone)
                          (NN:[1319..1329] conversion))
                      (PP (IN:[1330..1334] into)
                        (NP (NN:[1335..1347] progesterone))))))))
            (ADVP-TMP-2 (-NONE-:[1347..1347] *T*))))))
    (,:[1347..1348] ,)
    (NP-SBJ
      (NP (DT:[1349..1350] a) (JJR:[1351..1357] higher)
          (NN:[1358..1370] pregnenolone) (NN:[1371..1383] accumulation))
      (PP-1 (-NONE-:[1383..1383] *ICH*)))
    (VP (VBD:[1384..1392] occurred)
      (PP-LOC (IN:[1393..1395] in)
        (NP
          (ADJP (NN:[1397..1400] TPA) (HYPH:[1400..1401] -)
                (VBN:[1401..1415] differentiated))
          (NNS:[1416..1421] cells)))
      (PP-1 (IN:[1422..1426] than)
        (PP-LOC (IN:[1427..1429] in)
          (NP
            (ADJP (NN:[1430..1432] RA) (HYPH:[1432..1433] -)
                  (VBN:[1433..1447] differentiated))
            (NNS:[1448..1452] ones)))))
    (.:[1452..1453] .)))

;sentence 10 Span:1454..1653
;Although SU 10603, a  blocker of 17alpha-hydroxylase/c17,20-lyase enzyme
;involved in DHEA formation  from pregnenolone, gave rise to an elevated
;neurosteroid content only in  RA-differentiated cells.
;[1463..1471]:substance:"SU 10603"
;[1476..1483]:substance:"blocker"
;[1487..1506]:substance:"17alpha-hydroxylase"
;[1507..1526]:substance:"c17,20-lyase enzyme"
;[1539..1543]:substance:"DHEA"
;[1560..1572]:substance:"pregnenolone"
;[1599..1611]:substance:"neurosteroid"
;[1629..1631]:substance:"RA"
(SENT
  (S
    (ADVP (IN:[1454..1462] Although))
    (NP-SBJ
      (NP (NN:[1463..1465] SU) (CD:[1466..1471] 10603))
      (,:[1471..1472] ,)
      (NP
        (NP
          (NP (DT:[1473..1474] a) (NN:[1476..1483] blocker))
          (PP (IN:[1484..1486] of)
            (NP
              (NML (NN:[1487..1506] 17alpha-hydroxylase) (SYM:[1506..1507] /)
                   (NN:[1507..1519] c17,20-lyase))
              (NN:[1520..1526] enzyme))))
        (VP (VBN:[1527..1535] involved)
          (NP (-NONE-:[1535..1535] *))
          (PP-CLR (IN:[1536..1538] in)
            (NP
              (NP (NN:[1539..1543] DHEA) (NN:[1544..1553] formation))
              (PP (IN:[1555..1559] from)
                (NP (NN:[1560..1572] pregnenolone))))))))
    (,:[1572..1573] ,)
    (VP (VBD:[1574..1578] gave)
      (NP-CLR (NN:[1579..1583] rise))
      (PP-CLR (TO:[1584..1586] to)
        (NP (DT:[1587..1589] an) (VBN:[1590..1598] elevated)
            (JJ:[1599..1611] neurosteroid) (NN:[1612..1619] content)))
      (PP-LOC (RB:[1620..1624] only) (IN:[1625..1627] in)
        (NP
          (ADJP (NN:[1629..1631] RA) (HYPH:[1631..1632] -)
                (VBN:[1632..1646] differentiated))
          (NNS:[1647..1652] cells))))
    (.:[1652..1653] .)))

;sentence 11 Span:1654..1756
;No difference in pregnenolone levels was found in  undifferentiated cells
;treated with each inhibitor.
;[1671..1683]:substance:"pregnenolone"
;[1746..1755]:substance:"inhibitor"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1654..1656] No) (NN:[1657..1667] difference))
      (PP (IN:[1668..1670] in)
        (NP (NN:[1671..1683] pregnenolone) (NNS:[1684..1690] levels))))
    (VP (VBD:[1691..1694] was)
      (VP (VBN:[1695..1700] found)
        (NP-1 (-NONE-:[1700..1700] *))
        (PP-LOC (IN:[1701..1703] in)
          (NP
            (NP (JJ:[1705..1721] undifferentiated) (NNS:[1722..1727] cells))
            (VP (VBN:[1728..1735] treated)
              (NP (-NONE-:[1735..1735] *))
              (PP (IN:[1736..1740] with)
                (NP (DT:[1741..1745] each) (NN:[1746..1755] inhibitor))))))))
    (.:[1755..1756] .)))

;sentence 12 Span:1757..1901
;Thus, differentiation seems  to promote pregnenolone-metabolizing enzyme
;activities that may vary upon  phenotypic changes induced by RA or TPA.
;[1797..1829]:substance:"pregnenolone-metabolizing enzyme"
;[1891..1893]:substance:"RA"
;[1897..1900]:substance:"TPA"
(SENT
  (S
    (ADVP (RB:[1757..1761] Thus))
    (,:[1761..1762] ,)
    (NP-SBJ-2 (NN:[1763..1778] differentiation))
    (VP (VBZ:[1779..1784] seems)
      (S
        (NP-SBJ-2 (-NONE-:[1784..1784] *))
        (VP (TO:[1786..1788] to)
          (VP (VB:[1789..1796] promote)
            (NP
              (NP
                
                (ADJP (NN:[1797..1809] pregnenolone) (HYPH:[1809..1810] -)
                      (VBG:[1810..1822] metabolizing))
                (NN:[1823..1829] enzyme)
                (NNS:[1830..1840] activities))
              (SBAR
                (WHNP-1 (WDT:[1841..1845] that))
                (S
                  (NP-SBJ-1 (-NONE-:[1845..1845] *T*))
                  (VP (MD:[1846..1849] may)
                    (VP (VB:[1850..1854] vary)
                      (PP (IN:[1855..1859] upon)
                        (NP
                          (NP (JJ:[1861..1871] phenotypic)
                              (NNS:[1872..1879] changes))
                          (VP (VBN:[1880..1887] induced)
                            (NP (-NONE-:[1887..1887] *))
                            (PP (IN:[1888..1890] by)
                              (NP-LGS (NN:[1891..1893] RA) (CC:[1894..1896] or)
                                      (NN:[1897..1900] TPA)))))))))))))))
    (.:[1900..1901] .)))

;sentence 13 Span:1902..2137
;Treatments of differentiated cells with  the microtubule-depolymerizing drug
;colchicine and the actin  microfilament-altering agent cytochalasin D
;decreased pregnenolone synthesis  without affecting cell viability or
;cytP450scc amount.
;[1974..1978]:substance:"drug"
;[1979..1989]:substance:"colchicine"
;[1998..2033]:substance:"actin  microfilament-altering agent"
;[2034..2048]:substance:"cytochalasin D"
;[2059..2071]:substance:"pregnenolone"
;[2119..2129]:cyp450:"cytP450scc"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1902..1912] Treatments))
      (PP (IN:[1913..1915] of)
        (NP (VBN:[1916..1930] differentiated) (NNS:[1931..1936] cells)))
      (PP (IN:[1937..1941] with)
        (NP
          (NP
            (NP (DT:[1943..1946] the)
              (ADJP (NN:[1947..1958] microtubule) (HYPH:[1958..1959] -)
                    (VBG:[1959..1973] depolymerizing))
              (NN:[1974..1978] drug))
            (NP (NN:[1979..1989] colchicine)))
          (CC:[1990..1993] and)
          (NP
            (NP (DT:[1994..1997] the)
              
              (ADJP
                (NML (NN:[1998..2003] actin) (NN:[2005..2018] microfilament))
                (HYPH:[2018..2019] -) (VBG:[2019..2027] altering))
              (NN:[2028..2033] agent))
            (NP (NN:[2034..2046] cytochalasin) (NN:[2047..2048] D))))))
    (VP (VBD:[2049..2058] decreased)
      (NP (NN:[2059..2071] pregnenolone) (NN:[2072..2081] synthesis))
      (PP-MNR (IN:[2083..2090] without)
        (S-NOM
          (NP-SBJ (-NONE-:[2090..2090] *))
          (VP (VBG:[2091..2100] affecting)
            (NP
              (NP (NN:[2101..2105] cell) (NN:[2106..2115] viability))
              (CC:[2116..2118] or)
              (NP (NN:[2119..2129] cytP450scc) (NN:[2130..2136] amount)))))))
    (.:[2136..2137] .)))

;sentence 14 Span:2138..2395
;Addition of the  cell-permeant cholesterol analogue 22R-hydroxycholesterol
;known to elude  cholesterol transport systems induced pregnenolone synthesis,
;however,  indicating that perturbations in cytoskeleton likely affect
;endogenous  cholesterol transport.
;[2169..2189]:substance:"cholesterol analogue"
;[2190..2212]:substance:"22R-hydroxycholesterol"
;[2229..2240]:substance:"cholesterol"
;[2267..2279]:substance:"pregnenolone"
;[2373..2384]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2138..2146] Addition))
      (PP (IN:[2147..2149] of)
        (NP
          (NP
            (NP (DT:[2150..2153] the)
              (ADJP (NN:[2155..2159] cell) (HYPH:[2159..2160] -)
                    (JJ:[2160..2168] permeant))
               (NN:[2169..2180] cholesterol) (NN:[2181..2189] analogue))
            (NP (NN:[2190..2212] 22R-hydroxycholesterol)))
          (VP (VBN:[2213..2218] known)
            (S
              (NP-SBJ (-NONE-:[2218..2218] *))
              (VP (TO:[2219..2221] to)
                (VP (VB:[2222..2227] elude)
                  (NP (NN:[2229..2240] cholesterol) (NN:[2241..2250] transport)
                      (NNS:[2251..2258] systems)))))))))
    (VP (VBD:[2259..2266] induced)
      (NP (NN:[2267..2279] pregnenolone) (NN:[2280..2289] synthesis))
      (,:[2289..2290] ,)
      (ADVP (RB:[2291..2298] however))
      (,:[2298..2299] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[2299..2299] *))
        (VP (VBG:[2301..2311] indicating)
          (S (IN:[2312..2316] that)
            (S
              (NP-SBJ
                (NP (NNS:[2317..2330] perturbations))
                (PP-LOC (IN:[2331..2333] in)
                  (NP (NN:[2334..2346] cytoskeleton))))
              (ADVP (RB:[2347..2353] likely))
              (VP (VBP:[2354..2360] affect)
                (NP (JJ:[2361..2371] endogenous) (NN:[2373..2384] cholesterol)
                    (NN:[2385..2394] transport))))))))
    (.:[2394..2395] .)))

;sentence 15 Span:2396..2644
;The relevance of this finding may rest on the observed  involvement of
;cytoskeletal organization in such events as neuronal plasticity,  cognitive
;function and also neurodegenerative disorders in which neurosteroids  have
;been shown to have a part.
;[2598..2611]:substance:"neurosteroids"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2396..2399] The) (NN:[2400..2409] relevance))
      (PP (IN:[2410..2412] of)
        (NP (DT:[2413..2417] this) (NN:[2418..2425] finding))))
    (VP (MD:[2426..2429] may)
      (VP (VB:[2430..2434] rest)
        (PP (IN:[2435..2437] on)
          (NP
            (NP (DT:[2438..2441] the) (VBN:[2442..2450] observed)
                (NN:[2452..2463] involvement))
            (PP (IN:[2464..2466] of)
              (NP (JJ:[2467..2479] cytoskeletal) (NN:[2480..2492] organization)))
            (PP-LOC (IN:[2493..2495] in)
              (NP
                (NP (JJ:[2496..2500] such) (NNS:[2501..2507] events))
                (PP (IN:[2508..2510] as)
                  (NP
                    (NP (JJ:[2511..2519] neuronal) (NN:[2520..2530] plasticity))
                    (,:[2530..2531] ,)
                    (NP (JJ:[2533..2542] cognitive) (NN:[2543..2551] function))
                    (CC:[2552..2555] and) (RB:[2556..2560] also)
                    (NP (JJ:[2561..2578] neurodegenerative)
                        (NNS:[2579..2588] disorders))))
                (SBAR
                  (WHPP-2 (IN:[2589..2591] in)
                    (WHNP (WDT:[2592..2597] which)))
                  (S
                    (NP-SBJ-1 (NNS:[2598..2611] neurosteroids))
                    (VP (VBP:[2613..2617] have)
                      (VP (VBN:[2618..2622] been)
                        (VP (VBN:[2623..2628] shown)
                          (S
                            (NP-SBJ-1 (-NONE-:[2628..2628] *))
                            (VP (TO:[2629..2631] to)
                              (VP (VB:[2632..2636] have)
                                (NP (DT:[2637..2638] a) (NN:[2639..2643] part))
                                (PP-2 (-NONE-:[2643..2643] *T*))))))))))))))))
    (.:[2643..2644] .)))

;section 16 Span:2645..2676
;Copyright 2000 Wiley-Liss, Inc.
(SEC
  (FRAG (NN:[2645..2654] Copyright) (CD:[2655..2659] 2000)
        (NNP:[2660..2665] Wiley) (HYPH:[2665..2666] -) (NNP:[2666..2670] Liss)
        (,:[2670..2671] ,) (NNP:[2672..2676] Inc.)))

;section 17 Span:2680..2725
;PMID: 10820437 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2680..2684] PMID) (::[2684..2685] :) (CD:[2686..2694] 10820437)
        (NN:[2695..2696] -LSB-) (NNP:[2696..2702] PubMed) (::[2703..2704] -)
        (NN:[2705..2712] indexed) (IN:[2713..2716] for)
        (NNP:[2717..2725] MEDLINE-RSB-)))
